Last updated on June 2018

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia


Brief description of study

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia

Detailed Study Description

Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion, first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia (AML).

The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-90009, The expansion part (Part B) will further evaluate the safety and efficacy of CC-90009 administered at or below the maximum tolerated dose (MTD) in selected expansion cohorts of in order to determine the recommended Phase 2 dose (RP2D).

Clinical Study Identifier: NCT02848001

Contact Investigators or Research Sites near you

Start Over

Associate Director Clinical Trial Disclosure

Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie
Villejuif, France
6.87miles
  Connect »